241 related articles for article (PubMed ID: 20567009)
1. Oral bisphosphonate use and breast cancer incidence in postmenopausal women.
Chlebowski RT; Chen Z; Cauley JA; Anderson G; Rodabough RJ; McTiernan A; Lane DS; Manson JE; Snetselaar L; Yasmeen S; O'Sullivan MJ; Safford M; Hendrix SL; Wallace RB
J Clin Oncol; 2010 Aug; 28(22):3582-90. PubMed ID: 20567009
[TBL] [Abstract][Full Text] [Related]
2. Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid.
Hue TF; Cummings SR; Cauley JA; Bauer DC; Ensrud KE; Barrett-Connor E; Black DM
JAMA Intern Med; 2014 Oct; 174(10):1550-7. PubMed ID: 25111880
[TBL] [Abstract][Full Text] [Related]
3. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.
Sebba AI
Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
5. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
7. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
[TBL] [Abstract][Full Text] [Related]
8. Oral bisphosphonate use and colorectal cancer incidence in the Women's Health Initiative.
Passarelli MN; Newcomb PA; LaCroix AZ; Lane DS; Ho GY; Chlebowski RT
J Bone Miner Res; 2013 Sep; 28(9):2043-8. PubMed ID: 23519920
[TBL] [Abstract][Full Text] [Related]
9. Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort Study.
Pazianas M; Abrahamsen B; Eiken PA; Eastell R; Russell RG
Osteoporos Int; 2012 Nov; 23(11):2693-701. PubMed ID: 22392160
[TBL] [Abstract][Full Text] [Related]
10. A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk.
Nayak S; Greenspan SL
Osteoporos Int; 2019 Apr; 30(4):705-720. PubMed ID: 30623214
[TBL] [Abstract][Full Text] [Related]
11. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
Davis S; Martyn-St James M; Sanderson J; Stevens J; Goka E; Rawdin A; Sadler S; Wong R; Campbell F; Stevenson M; Strong M; Selby P; Gittoes N
Health Technol Assess; 2016 Oct; 20(78):1-406. PubMed ID: 27801641
[TBL] [Abstract][Full Text] [Related]
12. Oral bisphosphonate use and lung cancer incidence among postmenopausal women.
Tao MH; Chen S; Freudenheim JL; Cauley JA; Johnson KC; Mai X; Sarto GE; Wakelee H; Boffetta P; Wactawski-Wende J
Ann Oncol; 2018 Jun; 29(6):1476-1485. PubMed ID: 29617712
[TBL] [Abstract][Full Text] [Related]
13. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
Ringe JD; Möller G
Rheumatol Int; 2009 Dec; 30(2):213-21. PubMed ID: 19430791
[TBL] [Abstract][Full Text] [Related]
14. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer.
Monsees GM; Malone KE; Tang MT; Newcomb PA; Li CI
J Natl Cancer Inst; 2011 Dec; 103(23):1752-60. PubMed ID: 22021667
[TBL] [Abstract][Full Text] [Related]
16. Hip fractures in users of first- vs. second-generation bisphosphonates.
Mamdani M; Kopp A; Hawker G
Osteoporos Int; 2007 Dec; 18(12):1595-600. PubMed ID: 17767369
[TBL] [Abstract][Full Text] [Related]
17. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
[TBL] [Abstract][Full Text] [Related]
18. Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis?
Sawka AM; Ioannidis G; Papaioannou A; Thabane L; Olszynski WP; Brown JP; Hanley DA; Murray TM; Josse RG; Sebaldt RJ; Petrie A; Tenenhouse A; Goldsmith CH; Boulos P; Kouroukis T; Adachi JD
J Obstet Gynaecol Can; 2005 Aug; 27(8):759-64. PubMed ID: 16287007
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonate use and the risk of breast cancer: a meta-analysis of observational studies.
Ou YJ; Chiu HF; Wong YH; Yang CC; Yang YH
Pharmacoepidemiol Drug Saf; 2017 Oct; 26(10):1286-1295. PubMed ID: 28857419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
